不同克拉霉素剂型治疗幽门螺杆菌感染的疗效分析

目的探讨不同克拉霉素剂型治疗幽门螺杆菌感染的疗效。方法回顾性分析2013年10月至2019年6月间就诊使用含克拉霉素铋剂四联方案进行幽门螺杆菌根除治疗的患者资料,比较两种不同克拉霉素制剂(速释片与缓释片)治疗幽门螺杆菌感染的根除率。结果共有316例符合条件的患者纳入本研究,其中,速释片组169例,缓释片组147例;胃镜检查及病理活检结果显示,所有受试者均存在慢性胃炎,其中速释片组慢性活动性胃炎157例,伴慢性萎缩性胃炎57例,伴胃或十二指肠溃疡35例,伴低级别上皮内瘤变1例,早期胃癌1例;缓释片组慢性活动性胃炎130例,伴慢性萎缩性胃炎45例,伴胃或十二指肠溃疡26例,无上皮内瘤变或癌变病例,两组各种病变间差异均无统计学意义(P均>0.05)。速释片组的幽门螺杆菌根除率为90.53%(153/169),缓释片组的幽门螺杆菌根除率为80.27%(118/147),速释片组明显高于缓释片组(P<0.05)。结论含克拉霉素铋剂四联方案根除治疗幽门螺杆菌感染的效果速释片优于缓释片,临床应用中建议优先选择克拉霉素速释片。

Objective To investigate the eficacy of different clarithromycin preparations in the treatment of Helicobacter pylori infection.Methods The patients'data who were received clarithromycin bismuth-containing quadruple regimen for the treatment of Helicobacter pylori infection in our hospital between October 2013 to June 2019 were retrospectively analyzed,and the eficacy of diferent clarithromycin preparations(rapid-release tablets and sustained-release tablets)in the treatment of Helicobacter pylori infection were statistically analyzed.Results A total of 316 eligible patients were included in this study.Among them,169 were in the rapid-release tablets group and 147 were in the sustained-release tablets group.Results A total of 316 eligible patients were enrolled in the study,There were 157 cases of chronic active gastritis,57 cases of chronic atrophic gastritis,35 cases of peptic ulcer,1 case of low grade intraepithelial neoplasia,1 case of early gatric cancer in the rapid release tablets group;and there were 130 cases of chronic active gastritis,45 cases of chronic atrophic gastritis,26 cases of peptic ulcer,and no low grade intraepithelial neoplasia or early gastric cancer in the sustained-release tablets group.There was no statistical difference of these diseases between the two groups(P>0.05).The eradication rate of the treatment of Helicobacter pylori was 90.53%(153/169)in the rapid-release tablets group and 80.27%(118/147)in the sustained-release tablets group,and the rapid-release tablets group was significantly higher than the sustained-release tablets group(P<0.05).Conclusion The efficacy of the rapid-release tablets is better than the sustained-release tablets in the treatment of Helicobacter pylori infection with the clarithromycin bismuth-containing quadruple regimen.So it is suggested that clarithromycin rapid release tablets should be preferred in clinical application.